

# Pulmonary Hypertension in the Intensive Care Unit (ICU) - Swiss Survey 1

<b>Submission date</b> 06/09/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/10/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 28/10/2010	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Urs Wenger

**Contact details**  
University Hospital Zürich  
Rämistrasse 100  
Zürich  
Switzerland  
8091

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

## Study information

**Scientific Title**

A prospective multicentre study to investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension in the Intensive Care Unit (ICU)

**Acronym**

PHICUSS1

**Study objectives**

To investigate the prevalence, causes, diagnostic and therapeutic approach of pulmonary hypertension (PH) of any cause in the setting of surgical, medical or interdisciplinary Intensive Care Units (ICUs) of primary, secondary and tertiary Swiss hospitals.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics approval was not required for this study.

**Study design**

Prospective multicentre study

**Primary study design**

Observational

**Secondary study design**

Non randomised controlled trial

**Study setting(s)**

Hospital

**Study type(s)**

Screening

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Pulmonary hypertension

**Interventions**

The current characteristics, local facilities, diagnostic and therapeutic attitude against PH of the participating ICUs are assessed prior to study beginning by a questionnaire (hospital form).

During the study period all consecutive patients admitted to ICU for any reason are screened for presence or suspicion of PH. If PH is present or suspected the most probable causes, diagnostic and therapeutic attitude, clinical, laboratory, haemodynamic data (if measured) and 30 days survival will be assessed by a questionnaire (patient form).

Participating centres are asked to complete the hospital form only once, before study begin. Thereafter, during the enrolment period all patients admitted to the participating ICU are screened by use of the patient form. Only if PH is present, suspected or disclosed at ICU admission, or if risk factors for PH were present, additional information will be requested.

Data collection will be performed online using an electronic form of the data collection sheet.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

Prevalence of PH of any cause in the setting of surgical, medical or interdisciplinary ICUs. During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

### **Secondary outcome measures**

1. Causes of PH in the ICU setting
2. Diagnostic and therapeutic approach to PH by Swiss ICU physicians
3. 30 day outcome of patients admitted to ICU with suspected or confirmed PH

During the planned study period of 2 weeks enrolment of about 1000 patients is expected. It is a cross-sectional survey, only follow-up is 30 day mortality.

### **Overall study start date**

01/09/2009

### **Completion date**

30/09/2009

## **Eligibility**

### **Key inclusion criteria**

All consecutive patients (no age limit or gender restrictions) admitted to ICU for any reason

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Sex**

Both

### **Target number of participants**

1000

### **Key exclusion criteria**

Does not meet inclusion criteria

**Date of first enrolment**

01/09/2009

**Date of final enrolment**

30/09/2009

## **Locations**

**Countries of recruitment**

Switzerland

**Study participating centre**

University Hospital Zürich

Zürich

Switzerland

8091

## **Sponsor information**

**Organisation**

Swiss Society of Pulmonary Hypertension (Switzerland)

**Sponsor details**

c/o Institut für Medizin und Kommunikation (IMK) AG

Münsterberg 1

Basel

Switzerland

4001

**Sponsor type**

Research organisation

**Website**

<http://www.imk.ch/Intro/WebHome>

**ROR**

<https://ror.org/02c518c71>

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

Swiss Society of Intensive Care Medicine (Switzerland)

**Funder Name**

Actelion Pharma Schweiz AG (Switzerland)

**Funder Name**

Lung League Ticino (Switzerland)

## **Results and Publications**

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration